Skip to main content

Stemcell United Limited (SCU.AX)

Australian Securities Exchange Healthcare Drug Manufacturers - Specialty & GenericView data quality →
45.9Fair

ValueMarkers Composite Index

Top 15%#37,861 of 44,714

DCF data not available

Piotroski
3/9
Weak
Beneish
-10.00
Low Risk
Altman
-12.33
Distress
DCF Value
-
N/A
ROIC
-45.7%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Stemcell United Limited (SCU.AX) — VMCI valuation read

SCU.AX screens at VMCI 46/100, a 4-point gap below the Healthcare sector median (50). For a mid-cap Stemcell United Limited share, that placement says the multi-pillar composite is richer or lower quality than the typical peer on a like-for-like basis.

SCU.AX has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: SCU.AX trades at 14.0x earnings, 22% below the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 12.0% sits 2.0pp above the Healthcare median (10.0%), the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of 3.1x is the binding constraint on the bear case, which sets the rate-cycle exposure for Stemcell United Limited.

SCU.AX fell 2.9% over the trailing 7 days, with a -17.8% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in SCU.AX’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.